<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">S-1 might be another candidate for mild adjuvant chemotherapy for NSCLC. The oral fluoropyrimidine derivative which consists of tegafur and two modulators, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), enhances 5-FU efficacy by inhibiting degradation of 5-FU and reduces the GI toxicity caused by 5-FU [
 <xref ref-type="bibr" rid="CR5">5</xref>]. The significant effects with low adverse reactions of S-1 monotherapy in an adjuvant treatment have been proven in randomized phase III trials in digestive cancers including gastric, pancreatic and colon adenocarcinomas [
 <xref ref-type="bibr" rid="CR6">6</xref>–
 <xref ref-type="bibr" rid="CR8">8</xref>]. Accordingly, S-1 based adjuvant chemotherapy has been used as an option of standard treatment in intestinal cancers. Further, S-1 also has efficacy against squamous cell carcinomas including head and neck, oral, esophagus and thymus [
 <xref ref-type="bibr" rid="CR9">9</xref>–
 <xref ref-type="bibr" rid="CR11">11</xref>], suggesting S-1 is effective on both squamous carcinomas and adenocarcinomas.
</p>
